Publications – Agios Pharmaceuticals, Inc.

Year

Dec 11, 2023

Mitapivat Treatment Increases β-thalassemic Erythroblasts Energy Production and Responsiveness to Oxidative Stress

Source

ASH 2023

Dec 10, 2023

Functional and Multi-omics Signatures of Mitapivat Efficacy Upon Activation of Pyruvate Kinase in Red Blood Cells from Patients with Sickle Cell Disease

Source

ASH 2023

Dec 10, 2023

The Pyruvate Kinase (PK) Activator AG-946 Improves PK Properties and Red Blood Cell (RBC) Characteristics upon Ex Vivo Treatment of RBCs from Patients with Myelodysplastic Syndromes

Source

ASH 2023

Dec 10, 2023

Pyruvate Kinase Thermostability Is Associated with Red Blood Cell Adhesion, Deformability and Oxygen Affinity in Patients with Sickle Cell Disease

Source

ASH 2023

Dec 10, 2023

Longitudinal Characterization of Hemodynamic Changes with Multimodal Optical Techniques in Patients with Sickle Cell Disease Treated with Mitapivat

Source

ASH 2023

Dec 10, 2023

Understanding the Physical and Psychosocial Impacts of Pyruvate Kinase Deficiency: Patient-Led Development of the Pyruvate Kinase Deficiency Life Phase Model

Source

ASH 2023

Dec 10, 2023

One-Year Safety and Efficacy of Mitapivat in Sickle Cell Disease: Follow-Up Results of a Phase 2, Open-Label Study

Source

ASH 2023

Dec 10, 2023

Cross-community Collaboration and Data Collection to Optimize Patient Care in Hemolytic Anemias

Source

ASH 2023

Dec 09, 2023

Mitapivat Treatment Reduces Levels of Interference in Work/School Activity for Adult Patients with Pyruvate Kinase Deficiency

Source

ASH 2023

Dec 09, 2023

A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study of Mitapivat in Patients With Sickle Cell Disease: RISE UP Phase 2 Results

Source

ASH 2023

Dec 09, 2023

AG-946, An Activator of Pyruvate Kinase, Improves Ineffective Erythropoiesis in the Bone Marrow of Mouse Models of Myelodysplastic Syndromes

Source

ASH 2023

Dec 09, 2023

A Patient-Centric Approach to Sickle Cell Disease Clinical Trials: Integrating Patient Perspectives in the RISE UP Phase 2/3 Trial of Mitapivat for Informed Protocol Design and Associated Patient Community Benefit

Source

ASH 2023

Dec 09, 2023

Long-term Safety and Efficacy of Mitapivat, an Oral Pyruvate Kinase Activator, in Adults with Sickle Cell Disease: Extension of a Phase 1 Dose Escalation Study

Source

ASH 2023

Jun 09, 2023

AG-946, a Pyruvate Kinase Activator, Improves PK Properties and Red Blood Cell Metabolism upon Ex Vivo Treatment of RBCs from Patients with Myelodysplastic Syndromes

Source

EHA 2023 Annual Meeting

Jun 09, 2023

One year follow up of a phase 2 study of mitapivat, an oral pyruvate kinase activator, for the treatment of sickle cell disease

Source

EHA 2023 Annual Meeting

Jun 09, 2023

Mitapivat improves iron overload in patients with pyruvate kinase deficiency who are regularly transfused

Source

EHA 2023 Annual Meeting

Jun 09, 2023

Mitapivat Ameliorates in vitro Human β Thalassemic Erythroid Maturation Index and Modulates the Expression of the Cytoprotector Peroxiredoxin-2

Source

EHA 2023 Annual Meeting

Jun 09, 2023

Clinically relevant hemoglobin response in adults with pyruvate kinase deficiency treated with mitapivat – A sub-analysis of the ACTIVATE trial

Source

EHA 2023 Annual Meeting

Jun 09, 2023

Mitapivat efficacy in adults with pyruvate kinase deficiency and baseline hemoglobin levels >10 g/dL

Source

EHA 2023 Annual Meeting

Jun 09, 2023

The clinical characteristics and overall survival of patients with pyruvate kinase deficiency in the UK: a real world study

Source

EHA 2023 Annual Meeting

Jun 09, 2023

Healthcare Resource Use, Economic Burden, and Inpatient Morality in Patients With Alpha-or Beta-Thalassemia Compared With Matched Controls in the Real-World Setting

Source

EHA 2023 Annual Meeting

Jun 09, 2023

PKM and PKR Expression During Hematopoiesis and Erythropoiesis

Source

EHA 2023 Annual Meeting

Jun 09, 2023

Comorbidities and complications in adults with pyruvate kinase deficiency according to hemoglobin strata: A descriptive analysis from the Peak Registry

Source

EHA 2023 Annual Meeting

Jun 09, 2023

Rare Anaemia Disorders European Epidemiological Platform (RADeep): Distribution of Patients in Europe

Source

EHA 2023 Annual Meeting

For details on our former oncology programs, visit https://www.servier.us/.